Synta Pharmaceuticals Corp. (NASDAQ:SNTA) has been reiterated as a Buy at Cowen by research analyst Boris Peaker.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced updates to its clinical program for Ganetespib, a next-generation inhibitor of the chaperone protein Hsp90.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) announced that Phase 1 clinical results from three investigator-sponsored trials evaluating ganetespib combination therapy in ALK-positive lung cancer, platinum-resistant ovarian …
In a research note issued this morning, MLV analyst Arlinda Lee reiterated a Buy rating on Synta Pharmaceuticals Corp. (NASDAQ:SNTA) with a $6.
Roth Capital analyst Joseph Pantginis maintained a Buy rating on Synta Pharmaceuticals (NASDAQ:SNTA) with a $27 price target, as the company announced interim data from …
In a research report released Thursday, Roth Capital analyst Joseph Pantginis reaffirmed a Buy rating on Synta Pharmaceuticals (NASDAQ:SNTA) with a price target …
In a research note published yesterday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Synta Pharmaceuticals (SNTA) with a $27 price …
